AN OPEN LABEL DOSE RANGING, EFFICACY, SAFETY AND TOLERABILITY PHASE IIA STUDY OF TOPICAL RECOMBINANT LYSOSTAPHIN GEL FORMULATION IN SUBJECTS WITH UNCOMPLICATED STAPHYLOCOCCUS AUREUS SKIN AND SKIN STRUCTURE INFECTIONS.
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Lysostaphin (Primary)
- Indications Staphylococcal infections
- Focus Therapeutic Use
Most Recent Events
- 21 Jan 2012 New trial record